Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic
- Authors: Petrov A.M.1, Votintseva M.V.1, Stolyarov I.D.1
-
Affiliations:
- N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences
- Issue: Vol 16, No 2 (2022)
- Pages: 70-77
- Section: Reviews
- URL: https://journals.rcsi.science/2075-5473/article/view/124065
- DOI: https://doi.org/10.54101/ACEN.2022.2.8
- ID: 124065
Cite item
Full Text
Abstract
The safety of pathogenetic therapy for multiple sclerosis (MS) is a crucial aspect of the therapeutic strategy during the COVID-19 pandemic.
Based on our own data, obtained during the study of MS pathogenesis and safety analysis of MS disease-modifying therapies (DMTs), we hereby suggest a classification of DMTs side effects, based on their type, development, and direction of action. There is a need to thoroughly analyse adverse events caused by pathogenetic therapy, with a balanced assessment of the direct vs. adverse effects of immunosuppressive drugs.
Based on available literature, in the article, data on the effect of DMTs with various mechanisms of action on severe coronavirus infection are systematized.
Interferon-β and glatiramer acetate are the safest drugs to use during the COVID-19 pandemic. Teriflunomide, dimethyl fumarate, natalizumab, ocrelizumab, fingolimod, alemtuzumab, and cladribine should be used with caution. Drugs with a minor systemic immunosuppressant effect (e.g. natalizumab) and selective immunosuppressants (e.g. ocrelizumab) are safer than drugs that cause non-selective depletion of T and B cells.
It must be stressed that the risk of MS exacerbation and progression due to untimely prescription or cessation of pathogenetic therapy can significantly exceed the potential risk of COVID-19.
Long-term safety monitoring is required for DMTs during the COVID-19 pandemic and when the epidemiological situation stabilizes.
Full Text
##article.viewOnOriginalSite##About the authors
Andrey M. Petrov
N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences
Email: sid@ihb.spb.ru
ORCID iD: 0000-0001-9648-5492
Cand. Sci. (Med.), senior researcher, laboratory of neuroimmunology
Russian Federation, 197376, St. Petersburg, Academician Pavlov str., 9Marina V. Votintseva
N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences
Email: sid@ihb.spb.ru
ORCID iD: 0000-0002-0728-8903
junior researcher, Laboratory of neuroimmunology
Russian Federation, 197376, St. Petersburg, Academician Pavlov str., 9Igor D. Stolyarov
N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences
Author for correspondence.
Email: sid@ihb.spb.ru
ORCID iD: 0000-0001-8154-9107
D. Sci. (Med.), Prof., Head, Laboratory of neuroimmunology and MS center
Russian Federation, 197376, St. Petersburg, Academician Pavlov str., 9References
- Столяров И.Д., Петров А.М., Вотинцева М.В., Ивашкова Е.В. Безопасность иммуносупрессорных препаратов, изменяющих течение рассеянного склероза. Нервные болезни. 2018; 3: 16-21. Stolyarov I.D., Petrov A.M., Votintseva M.V., Ivashkova E.V. Safety of the immunosuppressing disease-modifying therapies in multiple sclerosis. Nervnye bolezni. 2018; 3: 16–21. doi: 10.24411/2071-5315-2018-12028
- World Health Organization. Coronavirus disease (COVID-19) situation reports. 2020. 11 March. URL: httph://www.int/ru/dg/speech-es/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid19
- Белопасов В.В., Яшу Я., Самойлова Е.М., Баклаушев В.П. Поражение нервной системы при СOVID-19. Клиническая практика. 2020; 11(2): 60–80. Belopasov V.V., Yashu Ya., Samoilova E.M., Baklaushev V.P. Damage to the nervous system in COVID-19. Klinicheskaya praktika. 2020; 11(2): 60–80. (In Russ.) doi: 10.17816/clinpract34851
- Román G.C., Spencer P.S., Reis J. et al. The neurology of COVID-19 revisited: a proposal from the environmental neurology specialty group of the world federation of neurology to implement international neurological registries. J. Neurol. Sci. 2020; 414: 116884. doi: 10.1016/j.jns.2020.116884
- Tsai S.T., Lu M.K., San S., Tsai C.H. The neurologic manifestations of Coronavirus Disease 2019 pandemic: a systemic review. Front. Neurol. 2020; 11: 498. doi: 10.3389/fneur.2020.00498
- Sepehrinezhad A., Shahbazi A., Negah S.S. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J. Neurovirol. 2020; 26(3): 324–329. doi: 10.1007/s13365-020-00851-2
- Vonck K., Garrez I., De Herdt V. et al. Neurological manifestations and neuroinvasive mechanisms of the severe acute respiratory syndrome Coronavirus Type 2. Eur. J. Neurol. 2020; 27(8): 1578–1587. doi: 10.1111/ene.14329
- Dalakas M.C. Guillain–Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflamm. 2020; 7(5): e781. doi: 10.1212/NXI.00000000000007811.
- Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 1–9. doi: 10.1001/jamaneurol.2020.1127.
- Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5
- Sellner J., Taba P., Öztürk S., Helbok R. The need for neurologists in the care of COVID-19 patients. Eur. J. Neurol. 2020; 27(9):e31–e32. doi: 10.1111/ene.14257
- Yashavantha Rao H.C., Jayabaskaran C. The emergence of a novel Coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. J. Med. Virol. 2020; 92(7): 786–790. doi: 10.1002/jmv.25918.53
- Robinson C.P., Busl K.M. Neurologic manifestations of severe respiratory viral contagions. Crit. Care Explor. 2020; 2(4): e0107. doi: 10.1097/CCE.0000000000000107
- Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229): 1033–1034. doi: 10.1016/S0140-6736(20)30628-0
- Zrzavy T., Wimmer I., Rommer P.S., Berger T. Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown. Eur. J. Neurol. 2021; 28(10): 3503–3516. doi: 10.1111/ene.14578
- Столяров И.Д., Петров А.М., Вотинцева М.В., Ивашкова Е.В. Нейроиммунология: теоретические и клинические аспекты. Физиология человека. 2013; 39(1): 51–59. Stolyarov I.D., Petrov A.M., Votintseva M.V., Ivashkova E.V. Neuroimmunology: theoretical and clinical aspects. Fiziologiya cheloveka. 2013; 39(1): 40–47. (In Russ.) doi: 10.7868/S0131164613010153
- Столяров И.Д., Петров А.М., Шкильнюк Г.Г. и др. Возможности позитронно-эмиссионной томографии для изучения механизмов развития рассеянного склероза (литературные и собственные данные). Журнал неврологии и психиатрии им. C.C. Корсакова. 2016; 116(2–2): 27–31. Stolyarov I.D., Petrov A.M., Shkilnyuk G.G. et al. Capabilities of positron emission tomography to study mechanisms of multiple sclerosis: own data and literature. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2016; 116(2–2): 27–31. (In Russ.) doi: 10.17116/jnevro20161162227-31
- Столяров И.Д., Петров А.М., Вотинцева М.В. Атрофия головного мозга и эффективность препаратов патогенетической терапии при рассеянном склерозе. Нервные болезни. 2017; 4: 10–17. Stolyarov I.D., Petrov A.M., Votintseva M.V. Atrophy of the brain and the efficiency of pathogenetic therapy in multiple sclerosis. Nervnye bolezni. 2017; 4: 10–17. (In Russ.)
- Кудрявцев И.В., Кробинец И.И., Минеев К.К. и др. Субпопуляционный состав Т-хелперов и цитотоксических Т-лимфоцитов периферической крови при рассеянном склерозе. Цитокины и воспаление. 2016; 15(1): 91–99. Kudryavtsev I.V., Krobinets I.I., Mineev K.K. et al. Helper and cytotoxic T lymphocyte subsets in patients with multiple sclerosis. Tsytokiny i vospalenie. 2016; 15(1): 91–99. (In Russ.)
- Минеeв К.К., Петров А.М., Вотинцева М.В., Столяров И.Д. Взаимосвязь двигательных и когнитивных нарушений при рассеянном склерозе. Анналы клинической и экспериментальной неврологии. 2020; 14(4): 23–28. Mineev K.K., Petrov A.M., Votintseva M.V., Stolyarov I.D. The correlation between motor and cognitive dysfunction in multiple sclerosis. Annals of clinical and experimental neurology. 2020; 14(4): 23–28. (In Russ.) doi: 10.25692/ACEN.2020.4.3
- Столяров И.Д., Петров А.М., Горохова Т.В. Терифлуномид в терапии ремиттирующего рассеянного склероза: эффективность и безопасность. Неврологический журнал. 2013; 18(2): 48–51. Stolyarov I.D., Petrov A.M., Gorohova T.V. Teriflunomide in treatment of remitting-relapsing multiple sclerosis: efficacy and safety. Nevrologicheskiy zhurnal. 2013; 18(2): 48–51. (In Russ.)
- Рекомендации по использованию новых препаратов для патогенетического лечения рассеянного склероза. М.; 2011. 141 с. Recommendations on the use of new drugs for the pathogenetic treatment of multiple sclerosis. Moscow; 2011. 141 p. (In Russ.)
- Бойко А.Н., Столяров И.Д., Сидоренко Т.В. и др. Патогенетическое лечение рассеянного склероза: настоящее и будущее. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009; 109 (7–2): 90–99. Boyko A.N., Stolyarov I.D., Sidorenko T.V. et al. Pathogenetic treatment of multiple sclerosis: present and future. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2009; 109 (7–2): 90–99. (In Russ.)
- Петров А.М., Ивашкова Е.В., Столяров И.Д. Новые возможности терапии вторично-прогрессирующего рассеянного склероза. Неврология, нейропсихиатрия, психосоматика. 2019; 11(4): 125–129. Petrov A.M., Stolyarov I.D., Ivashkova E.V. New possibilities for the therapy of secondary progressive multiple sclerosis. Nevrologiya, nejropsihiatriya, psihosomatika. 2019; 11(4): 125–129. (In Russ.) doi: 10.14412/2074-2711-2019-4-125-129
- Столяров И.Д., Петров А.М., Ивашкова Е.В., Вотинцева М.В. Исследования лекарственных средств при рассеянном склерозе: научные, клинические и этические аспекты. Неврологический журнал. 2018; 23(1): 16–22. Stolyarov I.D., Petrov A.M., Ivashkova E.V., Votintseva M.V. Drug research in multiple sclerosis: scientific, clinical, and ethical aspects. Nevrologicheskiy zhurnal. 2018; 23(1): 16–22. (In Russ.) doi: 10.18821/1560-9545-2018-23-1-16-21
- Вотинцева М.В., Петров А.М., Столяров И.Д. Препараты на основе моноклональных антител: настоящее и будущее в лечении рассеянного склероза (по материалам 32-го Конгресса Европейского комитета по лечению и исследованию рассеянного склероза — ECTRIMS). Анналы клинической и экспериментальной неврологии. 2017; 10(2): 83–88. Votintseva M.V., Petrov A.M., Stolyarov I.D. Monoclonal antibodies: present and future in the treatment of multiple sclerosis (based on the Proceedings of the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis — ECTRIMS)]. Annals of clinical and experimental neurology. 2017; 10(2): 83–88. (In Russ.) doi: 10.18454/ACEN.2017.2.12
- Рассеянный склероз. Моноклональная терапия / под ред. И.Д. Столя-рова. М.; 2019. 240 с. Stolyarov I.D. (ed.) Multiple sclerosis. Monoclonal therapy. Мoscow; 2019. 240 p. (In Russ.)
- Coles A.J., Twyman C.L., Arnold D.L. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1829–1839. doi: 10.1016/S0140-6736(12)61768-1
- Berger T., Elovaara I., Stolyarov I. et al. Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs. 2017; 31(1): 33-50. doi: 10.1007/s40263-016-0394-8
- Sallard E., Lescure F.X., Yazdanpanah Y. et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020; 178: 104791. doi: 10.1016/j.antiviral.2020.104791
- Reder A., Adamo A., Wicklein E.-M., Bhatti A. Use and safety of interferon beta-1b during the COVID-19 outbreak: current data from a pharmacovigilance safety database. ECTRIMS/ACTRIMS MSVirtual2020; 11–13 Sept 2020. URL: https://msvirtual2020.org/
- Zhang Q., Bastard P., Liu Z. et al. Inborn errors of type I IFN immunity in patients with life threatening COVID-19. Science. 2020; 370(6515): eabd4570. doi: 10.1126/science.abd4570
- Pairo-Castineira E., Clohisey S., Klaric L. et al. Genetic mechanisms of cri- tical illness in COVID-19. Nature. 2021; 591(7848): 92–98. doi: 10.1038/s41586-020-03065-y
- Bastard P., Rosen L.B., Zhang Q. et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515): eabd4585. doi: 10.1126/science.abd4585
- Reder A.T., Centonze D., Naylor M.L. et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021; 35: 317–330. doi: 10.1007/s40263-021-00804-1
- Bardaweel S.K., Hajjo R., Sabbah D.A. Sitagliptin: a potential drug for the treatment of COVID-19? Acta Pharm. 2021; 71: 175–184. doi: 10.2478/acph-2021-0013
- Solerte S.B., D’Addio F., Trevisan R. et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 dia- betes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020; 43: 2999–3006. doi: 10.2337/dc20-1521
- Ugwueze C.V., Ezeokpo B.C., Nnolim B.I. et al. COVID-19 and diabetes mellitus: the link and clinical implications. Dubai Diabetes Endocrinol. J. 2020; 26: 69–77.
- Al-Ani M., Elemam N.M., Hundt J.E., Maghazachi A.A. Drugs for multiple sclerosis activate natural killer cells: do they protect against COVID-19 Infection? Infect. Drug Resist. 2020; 13: 3243–3254. doi: 10.2147/IDR.S269797
- Alhakamy N.A., Ahmed O.A.A., Ibrahim T.S. et al. Evaluation of the antiviral activity of sitagliptin-glatiramer acetate nano-conjugates against SARS-CoV-2 virus. Pharmaceuticals (Basel). 2021; 14(3): 178. doi: 10.3390/ph14030178
- Capone F., Motolese F., Luce T. et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult. Scler. Relat. Disord. 2021; 48: 102734. doi: 10.1016/j.msard.2020.102734
- Ciardi M.R., Zingaropoli M.A., Pasculli P. et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. J. Neuroimmunol. 2020; 346: 577323. doi: 10.1016/j.jneuroim.2020.577323
- Maghzi A.H., Houtchens M.K., Preziosa P. et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J. Neurol. 2020; 267: 2790–2796. doi: 10.1007/s00415-020-09944-8
- Sormani M.P., De Rossi N., Schiavetti I. et al. Disease modifying therapies and COVID-19 severity in multiple sclerosis. Ann. Neurol. 2021; 89(4): 780–789. doi: 10.1002/ana.26028
- Salter A., Halper J., Bebo B. et al. COViMS Registry: clinical characterization of SARS-CoV-2 infected multiple sclerosis patients in North America. ECTRIMS/ACTRIMS MSVirtual2020; 11–13 Sept 2020. Abstract 2128. URL: https://msvirtual2020.org
- Landtblom A.M., Berntsson S.G., Boström I., Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol. Scand. 2021; 144(3): 229–235. doi: 10.1111/ane.13453
- Spelman T., Forsberg L., McKay K. et al. Increased rate of hospitalization for COVID-19 amongst Rituximab treated multiple sclerosis patients: a study of the Swedish MS Registry. Mult Scler. 2021; 13524585211026272. doi: 10.1177/13524585211026272
- Arrambide G., Llaneza-González M.Á., Costa-Frossard França L., et al. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1024. Published 2021 Jun 24. doi: 10.1212/NXI.0000000000001024
- Alonso R., Silva B., Garcea O. et al. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Mult. Scler. Relat. Disord. 2021; 51: 102886. doi: 10.1016/j.msard.2021.102886
- Bsteh G., Assar H., Hegen H. et al. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. PLoS One. 2021; 16(7): e0255316. doi: 10.1371/journal.pone.0255316
- Middleton R.M., Craig E.M., Rodgers W.J. et al. COVID-19 in multiple sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Mult. Scler. Relat. Disord. 2021; 56: 103317. doi: 10.1016/j.msard.2021.103317
- Louapre C., Collongues N., Stankoff B. et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020; 77: 1079–1088. doi: 10.1001/jamaneurol.2020.2581
- Simpson-Yap S., De Brouwer E., Kalincik T. et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021; 97(19): e1870–e1885. doi: 10.1212/WNL.0000000000012753
- Roach C.A., Cross A.H. Anti-CD20 B cell treatment for relapsing multiple sclerosis. Front. Neurol. 2021; 11: 595547. doi: 10.3389/fneur.2020.595547
- Giovannoni G., Hawkes C., Lechner-Scott J. et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult. Scler. Relat. Disord. 2020; 39: 102073. doi: 10.1016/j.msard.2020.102073
- Barun B., Gabelić T., Adamec I. et al. Influence of delaying ocrelizumab do-sing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult. Scler. Relat. Disord. 2021; 48: 102704. doi: 10.1016/j.msard.2020.102704
- Chen C., Shi L., Li Y. et al. Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia. Cell Biol. Toxicol. 2016; 32(3): 169–184. doi: 10.1007/s10565-016-9322-4
- Percopo C.M., Ma M., Brenner T.A. et al. Critical adverse impact of IL-6 in acute pneumovirus infection. J. Immunol. 2019; 202(3): 871–882. doi: 10.4049/jimmunol.1800927
- Loonstra F.C., Hoitsma E., van Kempen Z.L. et al. COVID-19 in multiple sclerosis: the Dutch experience. Mult. Scler. 2020; 26(10): 1256–1260. doi: 10.1177/1352458520942198
- Oran D.P., Topol E.J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann. Intern. Med. 2020; 173(5): 362–367. doi: 10.7326/M20-3012
- Meng Y., Wu Ping, Lu W. et al. Sex-specific clinical characteristics and pro- gnosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 2020; 16: e1008520. doi: 10.1371/journal.ppat.1008520
- Novi G., Mikulska M., Briano F. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult. Scler. Relat. Disord. 2020; 42: 102120. doi: 10.1016/j.msard.2020.102120
- Sormani M.P., De Rossi N., Schiavetti I. et al. Disease-modifying therapies and Coronavirus Disease 2019 severity in multiple sclerosis. Ann. Neurol. 2021; 89(4): 780–789. doi: 10.1002/ana.26028
- Costa G. D., Leocani L., Montalban X. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol. Sci. 2020; 41(7): 1647–1650. doi: 10.1007/s10072-020-04519-x
- Zheng C., Kar I., Chen C.K. et al. Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination. CNS Drugs. 2020; 34(9): 879–896. doi: 10.1007/s40263-020-00756-y
- Hojyo S., Uchida M., Tanaka K.et al. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 2020; 40: 37. doi: 10.1186/s41232-020-00146-3
- Iovino A., Olivieri N., Aruta F. et al. Alemtuzumab in COVID era. Mult. Scler. Relat. Disord. 2021; 51: 102908. doi: 10.1016/j.msard.2021.102908
- Centonze D., Rocca M.A., Gasperini C. et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J. Neurol. 2021; 268(11): 3961–3968. doi: 10.1007/s00415-021-10545-2
- Хачанова Н.В., Бахтиярова К.З., Бойко А.Н. и др. Обновленные рекомендации совета экспертов по применению и обеспечению безопасности терапии препаратом алемтузумаб (Лемтрада). Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(3): 82–91. Khachanova N.V., Bakhtiyarova K.Z., Boyko A.N. et al. Updated recommendations of the Council of Experts on the use and safety of therapy with alemtuzumab (Lemtrada). Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2020; 120(3): 82–91. (In Russ.) doi: 10.17116/jnevro202012003182
- Brownlee W., Bourdette D., Broadley S. et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020; 94(22): 949–952. doi: 10.1212/WNL.0000000000009507
- Berger J.R., Brandstadter R., Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol. Neuroimmunol. Neuroinflamm. 2020; 7(4): e761. doi: 10.1212/NXI.0000000000000761
- Ellul M.A., Benjamin L., Singh B. et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767–783. doi: 10.1016/S1474-4422(20)30221-0
- Baker D., Amor S., Kang A.S. et al. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult. Scler. Relat. Disord. 2020; 43: 102174. doi: 10.1016/j.msard.2020.102174
- Mallucci G., Zito A., Baldanti F. et al. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Mult. Scler. Relat. Disord. 2021; 49: 102754. doi: 10.1016/j.msard.2021.102754
- Rath L., Bui M.V., Ellis J. et al. Fast and safe: optimising multiple sclerosis infusions during COVID-19 pandemic. Mult. Scler. Relat. Disord. 2021; 47: 102642. doi: 10.1016/j.msard.2020.102642
- Diaz C., Zarco L.A., Rivera D.M. Highly active multiple sclerosis: an update. Mult. Scler. Relat. Disord. 2019; 30: 215–224. doi: 10.1016/j.msard.2019.01.039
- Comi G., Cook S., Giovannoni G. et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 2019; 29: 168–174. doi: 10.1016/j.msard.2019.01.038.
- Cook S., Leist Т., Comi G. et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult. Scler. Relat. Disord. 2019; 29: 157–167. doi: 10.1016/j.msard.2018.11.021
- Бахтиярова К.З., Бойко А.Н., Власов Я.В. и др. Рекомендации по использованию кладрибина в таблетках для патогенетического лечения пациентов с высокоактивным рассеянным склерозом. Неврология, нейропсихиатрия, психосоматика. 2020; 12(3): 93–99. Bakhtiyarova K.Z., Boyko A.N., Vlasov Ya.V. et al. Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis. Nevrologiya, nejropsihiatriya, psihosomatika. 2020; 12(3): 93–99. (In Russ.) doi: 10.14412/2074-2711-2020-3-93-99
- Preziosa P., Rocca M.A., Nozzolillo A. et al. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J. Neurol. 2020; 20: 1–3. doi: 10.1007/s00415-020-10309-4
- Celius E.G. Normal antibody response after COVID-19 during treatment with cladribine. Mult. Scler. Relat. Disord. 2020; 46: 102476. doi: 10.1016/j.msard.2020.102476
- Gelibter S., Orrico M., Filippi M., Moiola L. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? Mult. Scler. Relat. Disord. 2021; 49: 102775. doi: 10.1016/j.msard.2021.102775
- Zabalza S., Cárdenas-Robledo P., Tagliani G. et al. COVID-19 in MS patients: susceptibility, severity risk factors and serological response. Eur. J. Neurol. 2020; 19: ene.1469. doi: 10.1111/ene.14690
- Sellner J.; Rommer P.S. Multiple sclerosis and SARS-CoV-2 vaccination: considerations for immune-depleting therapies. Vaccines (Basel). 2021; 9(2): 99. doi: 10.3390/vaccines9020099
- Jack D., Damian D., Nolting A., Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult. Scler. Relat. Disord. 2021; 51: 102929. doi: 10.1016/j.msard.2021.102929
- Sormani M.P., Salvetti M., Labauge P. et al. DMTs and COVID-19 severity in MS: a pooled analysis from Italy and France. Ann. Clin. Transl. Neurol. 2021; 8(8): 1738–1744. doi: 10.1002/acn3.51408
- Wang N., Zhan Y., Zhu L. et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host. Microbe. 2020; 28(3): 455–464.e2. doi: 10.1016/j.chom.2020.07.005
- Alborghetti M., Bellucci G., Gentile A. et al. Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. Curr. Neuropharmacol. 2022; 20(1): 107–125. doi: 10.2174/1570159X19666210330094017
- Amor S., Baker D., Khoury S.J. et al. SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann. Neurol. 2020; 87: 794–797. doi: 10.1002/ana.25770. PMID: 32383812.
- Гусев Е.И., Мартынов М.Ю., Бойко А.Н. и др. Новая коронавирусная инфекция (COVID19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(6): 7–16. Gusev E.I., Martynov M.Yu., Boyko A.N. et al. New coronavirus infection (COVID19) and damage to the nervous system: mechanisms of neurological disorders, clinical manifestations, organization of neurological care. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2020; 120(6): 7–16. (In Russ.) doi: 10.17116/jnevro20201200617.
- Sastre-Garriga J., Tintore M., Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Mult. Scler. 2020; 26(10): 1153–1156. doi: 10.1177/1352458520931785
- Moss B.P., Mahajan K.R., Bermel R.A. et al. Multiple sclerosis management during the COVID-19 pandemic. Mult. Scler. J. 2020; 26: 1163–1171. doi: 10.1177/1352458520948231
- Portaccio E., Fonderico M., Hemmer B. et al. Impact of COVID-19 on multiple sclerosis care and management: results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult. Scler. 2022; 28(1): 132–138. doi: 10.1177/13524585211005339
- Chaudhry F., Jageka C., Levy P.D. et al. Review of the COVID-19 risk in multiple sclerosis. J. Cell Immunol. 2021; 3(2): 68–77. doi: 10.33696/immunology.3.080
- Sharifian-Dorche M., Sahraian M.A., Fadda G. et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review. Mult. Scler. Relat. Disord. 2021; 50: 102800. doi: 10.1016/j.msard.2021.102800